Literature DB >> 31029530

Plasma proteome profiling reveals differentially expressed lipopolysaccharide-binding protein among leptospirosis patients.

Cheng-Yee Fish-Low1, Leslie Thian Lung Than1, King-Hwa Ling2, Qingsong Lin3, Zamberi Sekawi4.   

Abstract

BACKGROUND: Human leptospirosis, or commonly known as "rat urine disease" is a zoonotic disease that is caused by the bacteria called Leptospira sp. The incidence rate of leptospirosis has been under-reported due to its unspecific clinical symptoms and the limitations of current laboratory diagnostic methods. Leptospirosis can be effectively treated with antibiotics in the early stage, and it is a curable disease but the accuracy to diagnose the infection is rarely achieved.
METHODS: The present pilot study investigated plasma protein profiles of leptospirosis patients and compared them against two control groups which consisted of dengue patients and healthy individuals. The plasma protein digests were analyzed using shotgun approach by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Protein abundances were estimated from the exponentially modified protein abundance index (emPAI) values. Plasma proteins in leptospirosis patients with at least two-fold differential expression compared to dengue and healthy control groups (p < 0.05, ANOVA) were identified.
RESULTS: Lipopolysaccharide (LPS)-binding protein (LBP) was found to be the only protein that has significant different expression between leptospirosis and the two control groups. The expression levels of leucine-rich alpha-2-glycoprotein (LRG1) and alpha-1-antichymotrypsin (ACT) were different significantly between leptospirosis and healthy group but not to the dengue control group.
CONCLUSION: This is the first plasma proteome-based study on leptospirosis that reports the differential expression of LBP compared to both dengue and healthy controls, which has not been previously reported in the context of leptospirosis.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Leptospirosis; Lipopolysaccharide-binding protein; Plasma proteome

Year:  2019        PMID: 31029530     DOI: 10.1016/j.jmii.2018.12.015

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  6 in total

Review 1.  Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review.

Authors:  Yonghui Zou; Yi Xu; Xiaofeng Chen; Yaoqi Wu; Longsheng Fu; Yanni Lv
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

2.  Proteomics-Based Approach to Identify Novel Blood Biomarker Candidates for Differentiating Intracerebral Hemorrhage From Ischemic Stroke-A Pilot Study.

Authors:  David Malicek; Ilka Wittig; Sebastian Luger; Christian Foerch
Journal:  Front Neurol       Date:  2021-12-17       Impact factor: 4.003

3.  A panel of urine-derived biomarkers to identify sepsis and distinguish it from systemic inflammatory response syndrome.

Authors:  Yao Tang; Ning Ling; Shiying Li; Juan Huang; Wenyue Zhang; An Zhang; Hong Ren; Yixuan Yang; Huaidong Hu; Xiaohao Wang
Journal:  Sci Rep       Date:  2021-10-21       Impact factor: 4.379

4.  Analysis of the Value of Serum Biomarker LBP in the Diagnosis of Spinal Tuberculosis.

Authors:  Caili Lou; Jian Liu; Zhibo Ren; Jinke Ji; Hongbao Ma; Hui Dong; Linan Wang; Xu Zhang; Ningkui Niu
Journal:  Infect Drug Resist       Date:  2022-08-29       Impact factor: 4.177

5.  Discovery of Schistosoma mekongi circulating proteins and antigens in infected mouse sera.

Authors:  Naphatsamon Uthailak; Poom Adisakwattana; Tipparat Thiangtrongjit; Yanin Limpanont; Phiraphol Chusongsang; Yupa Chusongsang; Kanthi Tanasarnprasert; Onrapak Reamtong
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

6.  Leptospiral LPS escapes mouse TLR4 internalization and TRIF‑associated antimicrobial responses through O antigen and associated lipoproteins.

Authors:  Delphine Bonhomme; Ignacio Santecchia; Frédérique Vernel-Pauillac; Martine Caroff; Pierre Germon; Gerald Murray; Ben Adler; Ivo G Boneca; Catherine Werts
Journal:  PLoS Pathog       Date:  2020-08-13       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.